ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 170 filers reported holding ENANTA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.43 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,576,925 | -47.0% | 409,700 | +1.5% | 0.00% | 0.0% |
| Q2 2023 | $8,641,391 | -45.9% | 403,803 | +2.2% | 0.00% | -50.0% |
| Q1 2023 | $15,976,887 | +90533.6% | 395,076 | +4.3% | 0.00% | 0.0% |
| Q4 2022 | $17,628 | -99.9% | 378,941 | +4.4% | 0.00% | -33.3% |
| Q3 2022 | $18,827,000 | +15.0% | 362,981 | +4.8% | 0.00% | +50.0% |
| Q2 2022 | $16,368,000 | -34.8% | 346,272 | -1.8% | 0.00% | -33.3% |
| Q1 2022 | $25,106,000 | -0.1% | 352,716 | +5.0% | 0.00% | 0.0% |
| Q4 2021 | $25,126,000 | +32.5% | 336,008 | +0.7% | 0.00% | 0.0% |
| Q3 2021 | $18,962,000 | +30.4% | 333,793 | +1.0% | 0.00% | +50.0% |
| Q2 2021 | $14,541,000 | -5.7% | 330,409 | +5.7% | 0.00% | 0.0% |
| Q1 2021 | $15,414,000 | +28.2% | 312,544 | +9.4% | 0.00% | 0.0% |
| Q4 2020 | $12,022,000 | -4.5% | 285,580 | +3.9% | 0.00% | 0.0% |
| Q3 2020 | $12,588,000 | -6.0% | 274,986 | +3.1% | 0.00% | -33.3% |
| Q2 2020 | $13,391,000 | +0.6% | 266,717 | +3.1% | 0.00% | 0.0% |
| Q1 2020 | $13,308,000 | -53.5% | 258,775 | -44.1% | 0.00% | 0.0% |
| Q4 2019 | $28,610,000 | +105.2% | 463,110 | +99.5% | 0.00% | 0.0% |
| Q3 2019 | $13,945,000 | -24.6% | 232,112 | +5.8% | 0.00% | -25.0% |
| Q2 2019 | $18,504,000 | -8.8% | 219,301 | +3.2% | 0.00% | -20.0% |
| Q1 2019 | $20,292,000 | -27.9% | 212,443 | -46.5% | 0.01% | +25.0% |
| Q4 2018 | $28,146,000 | +81.0% | 397,404 | +118.4% | 0.00% | 0.0% |
| Q3 2018 | $15,551,000 | -21.3% | 181,970 | +6.8% | 0.00% | -33.3% |
| Q2 2018 | $19,749,000 | +60.2% | 170,398 | +11.9% | 0.01% | +50.0% |
| Q1 2018 | $12,324,000 | +50.7% | 152,320 | +9.2% | 0.00% | +33.3% |
| Q4 2017 | $8,180,000 | +27.0% | 139,428 | +1.3% | 0.00% | +50.0% |
| Q3 2017 | $6,441,000 | +31.2% | 137,630 | +0.9% | 0.00% | 0.0% |
| Q2 2017 | $4,908,000 | +32.2% | 136,420 | +13.1% | 0.00% | 0.0% |
| Q1 2017 | $3,713,000 | -16.4% | 120,569 | -9.1% | 0.00% | 0.0% |
| Q4 2016 | $4,441,000 | +32.3% | 132,584 | +5.1% | 0.00% | 0.0% |
| Q3 2016 | $3,356,000 | +30.3% | 126,148 | +8.0% | 0.00% | +100.0% |
| Q2 2016 | $2,575,000 | -32.7% | 116,813 | -10.4% | 0.00% | -50.0% |
| Q1 2016 | $3,827,000 | +7.3% | 130,318 | +20.6% | 0.00% | 0.0% |
| Q4 2015 | $3,568,000 | +3.3% | 108,070 | +13.0% | 0.00% | 0.0% |
| Q3 2015 | $3,455,000 | -18.0% | 95,613 | +2.1% | 0.00% | 0.0% |
| Q2 2015 | $4,213,000 | +61.3% | 93,653 | +9.8% | 0.00% | +100.0% |
| Q1 2015 | $2,612,000 | -32.3% | 85,331 | +12.4% | 0.00% | -50.0% |
| Q4 2014 | $3,860,000 | +75.1% | 75,923 | +36.3% | 0.00% | +100.0% |
| Q3 2014 | $2,204,000 | +20.7% | 55,719 | +31.4% | 0.00% | 0.0% |
| Q2 2014 | $1,826,000 | +52.5% | 42,399 | +41.6% | 0.00% | 0.0% |
| Q1 2014 | $1,197,000 | +105.7% | 29,943 | +40.3% | 0.00% | – |
| Q4 2013 | $582,000 | +18.1% | 21,347 | -0.8% | 0.00% | – |
| Q3 2013 | $493,000 | +33.6% | 21,510 | +3.3% | 0.00% | – |
| Q2 2013 | $369,000 | – | 20,821 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 858,811 | $36,156,000 | 10.56% |
| Fairmount Funds Management LLC | 150,433 | $6,333,000 | 2.26% |
| ARMISTICE CAPITAL, LLC | 1,356,000 | $57,088,000 | 1.94% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,775,000 | $74,728,000 | 0.45% |
| Virtus ETF Advisers LLC | 14,321 | $603,000 | 0.25% |
| Granahan Investment Management | 231,071 | $9,728,000 | 0.22% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 248,320 | $10,454,000 | 0.09% |
| ACADIAN ASSET MANAGEMENT LLC | 467,514 | $19,684,000 | 0.08% |
| VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 126 | $5,000 | 0.08% |
| AIGEN INVESTMENT MANAGEMENT, LP | 12,854 | $541,000 | 0.07% |